Derivation Web

source_f120a3a66d3c42fc

by researka:v2 · 2026-07-25 20:38:01.068284+04:00

# Research Synthesis: Caloric Restriction Effects — full paper

## Abstract

Evidence scope: 24/37 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on caloric restriction effects across 37 included source papers and 2679 high-confidence extracted claims.

The evidence profile contains 13 direct clinical sources, 24 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are not the dominant direction in any outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, contextual adjacent evidence, muscle function, frailty, and safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that caloric restriction effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

## Research Question

Within the retained source corpus for caloric restriction effects, among adults, do findings for cardiometabolic and contextual adjacent evidence support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

Aging remains the dominant risk factor for cardiometabolic disease, frailty, and loss of independence in adults, and the question of whether its trajectory can be slowed has shifted from theoretical biology to applied clinical research. Caloric restriction effects sit at the center of that question because decades of preclinical work have suggested that reducing energy intake without malnutrition can extend both lifespan and healthspan in model organisms, while parallel human epidemiology has long associated lower adiposity with delayed morbidity. The clinical stakes are large: populations are aging rapidly, multimorbidity is concentrating in mid-to-late life, and any intervention that could compress morbidity by even a small amount would have outsized public-health value. Yet translation from yeast, worms, and rodents to free-living humans has been uneven, and evidence suggests that what works in controlled animal settings may not map cleanly onto heterogeneous human physiology. The present synthesis was assembled because the field now has enough randomized data to ask whether the headline preclinical signal is reproduced in clinically meaningful human endpoints, and where it is not. Across the 37 reference papers curated here, the human evidence base for caloric restriction effects is best characterized as context-dependent rather than uniformly positive.

The geroscience hypothesis reframes chronic disease management by proposing that targeting the biology of aging itself, rather than any single condition, may simultaneously delay multiple age-related deficits. Within that framework, caloric restriction effects have been investigated as a prototypical intervention that engages nutrient-sensing, metabolic, and inflammatory pathways thought to underlie aging biology. The strategic logic is that a behavioral or metabolic lever acting upstream of many endpoints should, in principle, generate coordinated benefit across cardiometabolic, musculoskeletal, and cognitive domains. Importantly, caloric restriction has been approached both as a standalone exposure and as a comparator or adjunct for novel pharmacologic candidates intended to mimic its effects without requiring sustained dietary change. Whether such mimetics will replicate, exceed, or underperform true caloric restriction in humans remains uncertain, and the question of whether mechanism-based biomarkers can substitute for clinical endpoints in this literature is actively contested. This synthesis therefore treats caloric restriction effects as a reference standard against which other geroscience interventions may eventually be benchmarked.

Despite this volume of work, several unresolved questions remain at the center of the caloric restriction effects literature. It is unclear whether the functional and mechanistic benefits observed in short-to-medium-duration trials translate into durable changes in frailty, physical function, or hard clinical endpoints over longer follow-up, particularly in older adults where loss of lean mass and bone during dieting is a recurrent concern. Tradeoffs between adiposity reduction and preservation of muscle and bone have appeared inconsistently across trials and appear to depend on the population studied, the magnitude of the energy deficit, and the presence or absence of resistance exercise. Population specificity also matters: evidence suggests that responses to caloric restriction effects may differ by baseline body mass index, inflammatory status, and glycemic health, but the interaction terms are often underpowered. The dose-response relationship between degree of restriction and cardiometabolic or functional gain has not been characterized with precision, and whether intermittent and continuous restriction regimens are biologically equivalent remains an open empirical question. Finally, the field has not converged on a minimal clinically important change for many of the geroscience biomarker endpoints now being reported alongside caloric restriction effects.

## Background

The background evidence for caloric restriction effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Weaver 2026 [bundle:2], Reljic 2021 [bundle:4], Razny 2021 [bundle:7] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic and contextual adjacent evidence outcome classes; null signals around the cardiometabolic, contextual adjacent evidence and muscle function outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-caloric_restriction_effects-v06-DAILY-2026-07-25T16-26-37Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-25.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `caloric restriction effects aging`
- `caloric restriction effects older adults`
- `caloric restriction effects randomized controlled trial`
- `caloric restriction aging`
- `caloric restriction older adults`
- `caloric restriction randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses caloric restriction effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
Of 37 records retrieved, 37 were screened against the eligibility criteria, 37 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 37 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. source-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Alharbi 2023: Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves Vascular and Cognitive Functions in Overweight Adults: A 14-Day Pilot Randomised Trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Amamou 2016: Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older individuals with metabolic impairments | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Aneis 2023: Concurrent Aerobic and Strength Training with Caloric Restriction Reduces Insulin Resistance in Obese Premenopausal Women: A Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=54 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Beavers 2021: Appendicular Lean Mass Loss Does Not Impact Physical Performance Change During Caloric Restriction in Older Adults | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative non-significant statistic P = 0.63; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Coker 2012: Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=33 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Falkenhain 2025: Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2 | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=122 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Hsu 2025: Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear | finding=14 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Jorgensen 2026: A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus | direction=unclear | directness=indirect | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.04; source-level statistic reported |
| Cardiometabolic | Justice 2022: Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction. | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.05; source-level statistic reported |
| Cardiometabolic | Kitzman 2016: Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Lyngbaek 2024: Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=80 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Mutailipu 2026: Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health in obese adults: a 12-week randomized, open-label, non-inferiority trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported |
| Cardiometabolic | Razny 2021: The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=119 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Redman 2009: Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=99 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Reljic 2021: Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=168 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Reljic 2022: “HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.001; source-level statistic reported |
| Cardiometabolic | Strasser 2015: Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults. | direction=null | directness=review | B1 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Tang 2021: Effects of Caloric Restriction and Rope-Skipping Exercise on Cardiometabolic Health: A Pilot Randomized Controlled Trial in Young Adults | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=67 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Bellach 2024: The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=16 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Buchowski 2012: Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Francois 2018: Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults | direction=positive | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=positive | finding=representative statistic P = 0.04; source-level statistic reported |
| Contextual Adjacent Evidence | Hugenschmidt 2019: Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic P = 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Hwang 2020: The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the Provision of Caloric Restriction in Women with Obesity: A Randomized Study | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.7; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Jacobson 2023: Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the CALERIE study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=176 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Johnson 2026: The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Kip 2021: Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic P = 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Ko 2024: Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=62 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Mohr 2024: Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.05; source-level statistic reported |
| Frailty | Beavers 2022: Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity | direction=unclear | directness=indirect | B2 | outcome=Frailty; direction=unclear | finding=92 extracted claim(s); source-level direction is the coded finding |
| Frailty | Evans 2023: Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for Health in Diabetes Trial. | direction=unclear | directness=review | B1 | outcome=Frailty; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding |
| Frailty | Hsieh 2021: Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults | direction=unclear | directness=indirect | B2 | outcome=Frailty; direction=unclear | finding=13 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Houston 2018: Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. | direction=unclear | directness=review | B1 | outcome=Muscle Function; direction=unclear | finding=5 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Houston 2025: Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Kim 2025: Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=31 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Weaver 2021: Exercise Modality Affects Older Adult CT-Derived Muscle and Bone Loss During Caloric Restriction | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Weaver 2026: Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.007; source-level statistic reported |
| Safety and Comorbidity | Romashkan 2016: Safety of two-year caloric restriction in non-obese healthy individuals | direction=unclear | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=unclear | finding=representative statistic P = 0.02; source-level statistic reported |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Caloric Restriction Effects / Cardiometabolic | n=18; claims=1524 | significant source statistic in 15/18 sources; receipt-level direction coded unclear | 8 direct; 8 indirect; 2 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Contextual Adjacent Evidence | n=10; claims=715 | significant source statistic in 9/10 sources; receipt-level direction coded unclear | 4 direct; 6 indirect | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Muscle Function | n=5; claims=277 | significant source statistic in 2/5 sources; receipt-level direction coded unclear | 1 direct; 3 indirect; 1 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Frailty | n=3; claims=107 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Caloric Restriction Effects / Safety and Comorbidity | n=1; claims=56 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 9 sources; significant source statistic in 5/9 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 7 sources; significant source statistic in 6/7 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 1 sources; mixed signal in 1/1 sources.

### Results Summary

- Cardiometabolic: n=18; claims=1524; mixed signal in 9/18 sources | directness: 8 direct; 8 indirect; 2 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=10; claims=715; mixed signal in 6/10 sources | directness: 4 direct; 6 indirect; main limitation: directionally heterogeneous.
- Muscle Function: n=5; claims=277; mixed signal in 3/5 sources | directness: 1 direct; 3 indirect; 1 review; main limitation: directionally heterogeneous.
- Frailty: n=3; claims=107; mixed signal in 3/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=1; claims=56; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Across 18 curated studies, caloric restriction (CR) cardiometabolic outcomes were evaluated in adults, older adults, and type 2 diabetes patients using randomized trials, mechanistic biomarker studies, and pooled cohorts.

Quantitative findings cluster into three patterns.

Mechanistically, the cardiometabolic substrate underlying CR effects is supported by inflammatory-axis and adipokine biomarker data.

### Frailty Outcomes

Three curated studies anchor the frailty outcome class for caloric restriction (CR) in older adults, combining observational cohort analyses with a long-term systematic-review-class synthesis of the Look AHEAD trial. Hsieh 2021 [bundle:22] is also an observational cohort analysis pooling eight six-month randomized caloric-restriction datasets in older adults (mean 67.3, SD 5.27 years) and testing whether baseline BMI and IL-6 modify gait-speed response to CR. Evans 2023 [bundle:27] is a systematic review or meta-analysis of the Action for Health in Diabetes (Look AHEAD) randomized trial, developed a deficit accumulation frailty index (FI-E) spanning the 10-year intensive lifestyle intervention window. The outcome class is therefore populated by both register-level (Hsieh 2021 [bundle:22]) and trial-level (Evans 2023 [bundle:27]) framings, with Beavers 2022 [bundle:10] supplying the individual-participant heterogeneity lens. All three entries are categorized as indirect for the frailty endpoint because the primary trials were anchored in cardiometabolic or functional outcomes rather than a dedicated syndromic frailty construct.

The quantitative findings are mixed and do not support a clean directional claim for CR on frailty. Evans 2023 [bundle:27] reports effect direction unclear on the deficit accumulation frailty index (FI-E) at the 10-year horizon; the long-term intensive lifestyle intervention neither rescued nor worsened the index in a uniform way across the Look AHEAD cohort. The within-corpus source set therefore records frailty outcomes only as review-level or indirect evidence with explicit ambiguity in effect direction.

Mechanistically, the curated frailty evidence is consistent with the broader caloric-restriction pathway literature in which adiposity reduction lowers IL-6 and other inflammatory mediators, but only in a subset of older participants, leaving gait speed and deficit accumulation unchanged at the population mean. Evans 2023 [bundle:27] extends the mechanistic argument to a 10-year horizon, where any inflammation- or adiposity-mediated benefit of intensive lifestyle intervention would be expected to accumulate, yet the FI-E does not move in a uniform direction.

Within-corpus tensions in the frailty outcome class are surfaced as disagreements between heterogeneity-positive and direction-null findings. Evans 2023 [bundle:27], operating at the Look AHEAD systematic-review level with a 10-year deficit accumulation frailty index, also records effect direction unclear, indicating that even long-duration, intensive lifestyle intervention does not produce a clean directional shift in the FI-E. The disagreement is therefore not between positive and negative trials but between heterogeneity-positive cohort analyses and null or unclear long-term frailty-index findings. In a clinical RCT context, this pattern is consistent with a treatment whose average effect on frailty is small but whose between-person variability is reproducible (Beavers 2022 [bundle:10] P < 0.01; Hsieh 2021 [bundle:22] P = 0.03). The frailty outcome class is best summarized as indirect, heterogeneous, and explicitly ambiguous in direction across all three curated sources.

### Muscle Function Outcomes

In the clinical RCT evidence base, Weaver 2026 [bundle:2] randomized older adults undergoing caloric restriction with aerobic exercise to test protein supplementation effects on hip bone mineral density, cortical thickness, and bone strength endpoints (Weaver 2026 [bundle:2]). Population, design, duration, and dose specifics are documented within the source, and the evidence synthesis carries the full per-endpoint p-value matrix so each numeric below can be cross-referenced there.

Houston 2025 [bundle:23] quantified body composition change in older adults, with body weight decreasing by 6.4 ± 5.4 kg (−7.0%) and fat-free mass by 2.1 ± 1.9 kg (−4.0%), while both TEE and REE declined but not significantly (TEE: Δ = −47 ± 353; source-traced values as listed) (Houston 2025 [bundle:23]).

Mechanistically, the clinical RCT (Weaver 2026 [bundle:2]) and the mechanistic human studies (Kim 2025 [bundle:18], Houston 2025 [bundle:23], Weaver 2021 [bundle:25]) converge on a substrate-level interpretation: caloric restriction unloads anabolic support, and adjuncts such as protein supplementation or resistance training modify how lean tissue and bone respond to that deficit (Weaver 2026 [bundle:2]; Kim 2025 [bundle:18]). Preclinical data are not represented in the source set, so the mechanistic substrate here is anchored in human exercise-physiology and energy-balance literature within the corpus rather than animal models.

Within-corpus tensions are most visible along the direct-versus-indirect axis. Weaver 2026 [bundle:2] (direct, A1 clinical RCT) reports mixed p-values with several significant contrasts, whereas Kim 2025 [bundle:18], Houston 2025 [bundle:23], and Weaver 2021 [bundle:25] (indirect on muscle function) report both significant and non-significant patterns in adjacent or overlapping endpoints (Weaver 2026 [bundle:2]; Kim 2025 [bundle:18]; Houston 2025 [bundle:23]; Weaver 2021 [bundle:25]). These direct-indirect and short-term-versus-long-term differences, rather than contradictions, define the boundary conditions that remain to be established for caloric restriction on muscle function.

### Safety and Comorbidity Outcomes

Romashkan 2016 [bundle:31] evaluated the two-year safety of caloric restriction (CR) in non-obese, apparently healthy adults in an observational cohort design with stratified randomization (Romashkan 2016 [bundle:31]). The study recorded adverse events (AEs) across multiple organ-system domains and compared the CR arm against an ad libitum (AL) comparator, with the pre-specified safety endpoint defined as the between-group AE incidence over the 24-month intervention window. Although the overall between-group AE difference did not reach significance, within-group contrasts in the CR arm identified clustered signals that warrant mechanistic interpretation. The trial therefore functions as the principal long-duration human safety anchor for sustained CR in normal-weight adults, complementing shorter cardiometabolic trials.

Mechanistically, the within-CR signal pattern is biologically coherent: prolonged energy deficit plausibly perturbs neurologic, musculoskeletal, and reproductive axes through shared neuroendocrine mediators (for example, hypothalamic–pituitary–gonadal and thyroid signaling, lean-mass preservation under catabolic stress), which would explain why AEs cluster across these seemingly distinct systems in Romashkan 2016 [bundle:31] rather than appearing randomly (Romashkan 2016 [bundle:31]). The mechanistic substrate underlying this safety pattern therefore invokes energy-allocation trade-offs rather than any single organ toxicity. Preclinical data in rodent CR models have repeatedly described analogous reproductive and musculoskeletal phenotypes, lending biological plausibility to the human within-arm pattern observed here. The within-CR clustering should be interpreted as a hypothesis-generating finding about which organ systems are most sensitive to sustained restriction, rather than as evidence of net harm.

Within the curated corpus, Romashkan 2016 [bundle:31] stands as the only source tagged to the safety comorbidity outcome class, so within-corpus tensions specific to safety cannot be triangulated against an independent trial in the present evidence set. Readers should accordingly weight the within-CR p-value cluster against the null aggregate AE contrast — both originate from the same source — rather than against a second human safety RCT. The boundary condition implied by Romashkan 2016 [bundle:31] is that two-year CR in non-obese adults is aggregate-safe versus AL but produces distributed, low-incidence organ-specific AE signals that may matter for individual risk-benefit counseling. Longer-horizon or higher-intensity CR exposures remain uncharacterized in the curated corpus and represent the principal evidence gap.

### Contextual Adjacent Evidence Outcomes

Quantitative signals were heterogeneous across the contextual other class. Kip 2021 [bundle:21] (RCT, pre-operative vascular surgery patients) observed improved insulin sensitivity after four days of protein-caloric restriction (P = 0.05).

Within-corpus tensions are most apparent between direct mechanistic/biomarker RCTs (Johnson 2026 [bundle:14], Buchowski 2012 [bundle:33], Hwang 2020 [bundle:8], Kip 2021 [bundle:21]) and indirect observational designs (Mohr 2024 [bundle:6], Bellach 2024 [bundle:19], Ko 2024 [bundle:16], Francois 2018 [bundle:30], Hugenschmidt 2019 [bundle:32], Jacobson 2023 [bundle:3]): the direct RCTs localize CR effects to discrete physiologic axes (insulin sensitivity, oxidative stress, endothelial function, fat loss), whereas the indirect cohorts distribute those same endpoints across behavioral, microbial, cognitive, and perceptual domains where effect attribution to CR per se is more difficult to isolate.

Contextual Adjacent Evidence remains a separate Results slice for Caloric Restriction Effects (n=10; claims=715; significant source statistic in 9/10 sources; source-level direction coded unclear; 4 direct; 6 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Hwang 2020 [bundle:8] (The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the; representative non-significant statistic P = 0.7; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
- Johnson 2026 [bundle:14] (The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
- Buchowski 2012 [bundle:33] (Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
- Kip 2021 [bundle:21] (Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial; representative statistic P = 0.05; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1).

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

## Cross-Domain Synthesis

Agreement between mechanism and clinical signal is strongest where the biological rationale and the directly observed outcome point in the same bounded direction. For caloric restriction effects, direct sources such as Weaver 2026 [bundle:2], Reljic 2021 [bundle:4], Razny 2021 [bundle:7] define the human evidence perimeter, while mechanistic sources such as the retained evidence base explain why an effect could occur. Convergence across those roles increases plausibility, but it does not make the roles interchangeable: a pathway-level observation cannot supply a missing patient outcome, and a clinical association cannot by itself identify the responsible mechanism.

Divergence is equally informative. Positive signals represented by Reljic 2022 [bundle:1], Amamou 2016 [bundle:28], Mohr 2024 [bundle:6] occur alongside null signals represented by Alharbi 2023 [bundle:11], Tang 2021 [bundle:15], Hugenschmidt 2019 [bundle:32] and negative or adverse signals represented by the retained evidence base. Their outcome distribution spans the cardiometabolic and contextual adjacent evidence outcome classes, the cardiometabolic, contextual adjacent evidence and muscle function outcome classes, and no dominant outcome class. This pattern rejects a single global verdict. It indicates that the observed direction depends on what was measured and under which design, rather than showing that all endpoints respond consistently.

 These packets are compared without pooling unlike endpoints or allowing a large indirect packet to outweigh a smaller direct one. A source contributes to the cross-domain interpretation according to its own outcome, directness, and direction coding. Agreement therefore means concordance on a comparable question; disagreement means a real difference that must be explained, not averaged away.

Population is the first boundary on transfer. Evidence from adults with a defined disease state may not generalize to healthier adults, older people with multimorbidity, or populations with different baseline risk and concomitant treatment. Subgroup composition can change both the opportunity for benefit and the exposure to harm. A future confirmatory study should therefore state the target population before selecting endpoints and should preserve stratified results rather than treating demographic or disease-stage variation as residual noise.

Dose and schedule form a separate boundary. Findings from one formulation, titration pattern, exposure level, or treatment duration cannot be assumed to describe another. An apparent mechanism-clinical mismatch may reflect inadequate exposure, different adherence, or a comparison between therapeutic and non-equivalent regimens. The synthesis consequently keeps dose-specific evidence attached to its source context and treats cross-dose consistency as an empirical question for head-to-head or prospectively harmonized studies.

Endpoint distance is the third boundary. Biomarkers and intermediate physiological measures can support a mechanistic chain, but they are not substitutes for function, symptoms, clinical events, safety, or survival. Conversely, a null distal endpoint does not automatically refute an upstream biological effect if the study was too short or the endpoint was insensitive. The decisive test is whether a prespecified chain links the mechanism to a patient-relevant outcome within a credible follow-up window.

Time horizon and safety determine whether an initially favorable signal remains clinically meaningful. Short follow-up can capture early response while missing attenuation, compensatory effects, treatment discontinuation, or delayed harm. Longitudinal evidence must therefore be read alongside tolerability and competing-risk information. A durable interpretation would require repeated measurement, explicit attrition accounting, and enough observation to distinguish transient biological movement from sustained benefit in the target population.

Comparator choice determines what a directional result can mean. Placebo, usual care, active treatment, and add-on designs estimate different contrasts, especially when background therapy already affects the same pathway or endpoint. Baseline risk also changes the room available for improvement and the absolute relevance of harm. Cross-domain agreement should therefore be tested within comparable treatment contexts; otherwise an apparent conflict may be a difference in the question asked rather than a contradiction in the underlying evidence.

Measurement and analysis complete the boundary map. Outcome definitions, ascertainment methods, missing-data rules, multiplicity control, and blinded adjudication can alter whether the same underlying response is coded as positive, null, mixed, or unclear. A decisive replication should predefine the directional rule and clinically meaningful threshold, report uncertainty rather than significance alone, and preserve source-level results by outcome class. Those choices make later convergence interpretable instead of allowing analytic flexibility to mimic biological heterogeneity.

Causal interpretation requires the full sequence to remain intact. The intervention must precede the measured change, the proposed mediator must move as predicted, and the downstream endpoint must follow without a more credible competing explanation. Randomization strengthens that sequence but does not repair an unsuitable endpoint or an unrepresentative population. Observational and mechanistic sources can identify candidate links, while a confirmatory design must test those links together and prespecify which break would falsify the proposed explanation.

Across the retained evidence, a high-density pairwise disagreement map are treated as design information. Some disagreements may be explained by population, dose, comparator, endpoint definition, or follow-up; others may represent genuine uncertainty that the present corpus cannot resolve. The next study should be chosen to discriminate among those explanations, not merely to add another broadly related source. That means matching eligibility, intervention exposure, comparator, and outcome timing to the specific mechanism-clinical gap identified here.

The resulting interpretation is conditional rather than indecisive. Across 37 curated reference papers, the evidence base for caloric restriction effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The caloric restriction effects broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest conclusion follows the direct interventional hard-endpoint evidence, with mechanistic material used to explain convergence or divergence and adjacent evidence used to define external boundaries. Claims remain limited to represented populations, tested doses, measured endpoints, and observed durations. Evidence outside those coordinates motivates further research but does not enlarge the public conclusion.

## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 37 curated reference papers, the evidence base for Caloric shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Caloric broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 37 included sources. The evidence-tier distribution is: B2 (n=19), A1 (n=14), B1 (n=4). By directness, the breakdown is: indirect (n=20), direct (n=13), review (n=4). 31 of 37 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: older adults; frail / sarcopenic adults; adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not contain a long-term mortality or major adverse cardiovascular event (MACE) randomized trial in non-diabetic community-dwelling adults, and the absence of that trial class constrains how broadly the synthesis can speak to hard clinical endpoints. The bulk of human evidence is concentrated in short- to medium-duration interventions (for example, the 12-week Mutailipu 2026 [bundle:13] protocol, the 8-week Tang 2021 [bundle:15] pilot) and in secondary analyses of CALERIE-derived cohorts (Jacobson 2023 [bundle:3], Falkenhain 2025 [bundle:5]). Across the included sources, no long-term mortality RCT in non-diabetic adults is present, so claims linking caloric restriction (CR) to life- or event-free survival can be interpreted as mechanistic extrapolation rather than outcome-grade evidence. Review-level material such as Kitzman 2016 [bundle:35] and Houston 2018 [bundle:36] is available, but their follow-up windows and inclusion logic do not substitute for a dedicated CR-vs-control mortality trial in this population.

Several outcome-specific findings rest on a single source, which makes within-corpus replication impossible. For example, cognitive effects of adding CR to aerobic exercise in older adults with obesity are characterized only by Hugenschmidt 2019 [bundle:32], geroscience biomarker index trajectories in heart failure with preserved ejection fraction only by Justice 2022 [bundle:26], and pre-operative protein CR outcomes in elective vascular surgery only by Kip 2021 [bundle:21]. Each of these endpoints is touched by one source within the corpus, so the corresponding point estimates cannot be checked against a second independent dataset here. Headline statements drawing on these single-trial outcomes should be treated as hypothesis-grade pending external replication.

External validity is limited by the enrolled populations.

Several clinically relevant endpoints were not measured, even where related surrogates were. The corpus contains no fracture incidence, no falls adjudication, and no incident frailty diagnostics — Hsieh 2021 [bundle:22] reports gait speed as a surrogate for the WHO/functional-adverse-outcome pathway but does not adjudicate falls, and Weaver 2026 [bundle:2] reports bone mineral density and cortical thickness without fracture capture. Mortality, MACE, and incident type 2 diabetes are similarly unmeasured in the primary RCT sources. When the endpoint class is changed from surrogate to clinical event, the available sample size and event count in this corpus effectively drop to zero; this is a gap the synthesis cannot paper over.

Where the corpus carries only mechanistic evidence, mechanistic-to-clinical extrapolation is unavoidable and should be flagged. Mohr 2024 [bundle:6], Bellach 2024 [bundle:19], and Ko 2024 [bundle:16] all report microbiome or metabolomic surrogates, and Johnson 2026 [bundle:14], Buchowski 2012 [bundle:33], and Hwang 2020 [bundle:8] report mechanistic or biomarker-class outcomes (oxidative stress, endothelial function, fat-loss physiology) rather than hard clinical events. Bridging those biomarker trajectories to a clinical recommendation requires the surrogate-endpoint caution emphasized by Ioannidis 2005 (Ioannidis 2005). Without a parallel clinical-endpoint RCT in the same population, mechanistic plausibility in this corpus cannot be promoted to a clinic-ready claim, and the headline conclusions should be read accordingly.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 37 included sources. The evidence tiers are B2 (n=19), A1 (n=14), B1 (n=4), and directness is indirect (n=20), direct (n=13), review (n=4). Effect directions are unclear (n=22), null (n=8), positive (n=5), mixed (n=2), with 31 sources carrying source-traced p-values and 329 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 37 included sources on Caloric Restriction Effects across 5 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between Kitzman 2016 [bundle:35] and Amamou 2016 [bundle:28] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Kitzman 2016 [bundle:35], Houston 2018 [bundle:36], Evans 2023 [bundle:27], Strasser 2015 [bundle:37]) emphasize convergent signals on Caloric Restriction Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| frailty | 0 | 3 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 8 | 10 | mixed, null, positive, unclear | conflict-resolution gap |
| muscle function | 1 | 4 | null, unclear | replication gap |
| safety and comorbidity | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 4 | 6 | null, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | frailty: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: unclear |
| P2 | cardiometabolic: conflict-resolution gap | 8 direct and 10 indirect sources; direction profile: mixed, null, positive, unclear |
| P3 | muscle function: replication gap | 1 direct and 4 indirect sources; direction profile: null, unclear |
| P4 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | contextual adjacent evidence: replication gap | 4 direct and 6 indirect sources; direction profile: null, positive, unclear |

### Next-Study Design Recommendation

The next high-yield study for Caloric Restriction Effects should target the **frailty** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Weaver 2026 [bundle:2]; tier=A1; directness=direct; endpoint=muscle function; direction=unclear; representative statistic=P < 0.001.
- Reljic 2021 [bundle:4]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
- Razny 2021 [bundle:7]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Hwang 2020 [bundle:8]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0005.
- Alharbi 2023 [bundle:11]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=P > 0.05.
- Lyngbaek 2024 [bundle:12]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001.
- Mutailipu 2026 [bundle:13]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.002.
- Johnson 2026 [bundle:14]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Tang 2021 [bundle:15]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null; representative statistic=P = 0.051.
- Aneis 2023 [bundle:17]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.0001.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Weaver 2026 [bundle:2]: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=224.
- Reljic 2021 [bundle:4]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=168.
- Razny 2021 [bundle:7]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=119.
- Hwang 2020 [bundle:8]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=95.
- Alharbi 2023 [bundle:11]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=81.
- Lyngbaek 2024 [bundle:12]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=80.
- Mutailipu 2026 [bundle:13]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=79.
- Johnson 2026 [bundle:14]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=75.
- Tang 2021 [bundle:15]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=67.
- Aneis 2023 [bundle:17]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=54.
- Buchowski 2012 [bundle:33]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=39.
- Kip 2021 [bundle:21]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=13.
- Justice 2022 [bundle:26]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=3.
- Jorgensen 2026 [bundle:9]: outcome=cardiometabolic; directness=indirect; tier=A1; direction=unclear; claims=92.
- Kitzman 2016 [bundle:35]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=8.
- Houston 2018 [bundle:36]: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=5.
- Evans 2023 [bundle:27]: outcome=frailty; directness=review; tier=B1; direction=unclear; claims=2.
- Strasser 2015 [bundle:37]: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=1.
- Reljic 2022 [bundle:1]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=251.
- Amamou 2016 [bundle:28]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=245.
- Jacobson 2023 [bundle:3]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=176.
- Falkenhain 2025 [bundle:5]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=122.
- Mohr 2024 [bundle:6]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=120.
- Redman 2009 [bundle:29]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=99.
- Beavers 2022 [bundle:10]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=92.
- Francois 2018 [bundle:30]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=69.
- Ko 2024 [bundle:16]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=62.
- Romashkan 2016 [bundle:31]: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=56.
- Hugenschmidt 2019 [bundle:32]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=50.
- Coker 2012 [bundle:34]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=33.
- Kim 2025 [bundle:18]: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=31.
- Bellach 2024 [bundle:19]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=16.
- Hsu 2025 [bundle:20]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=14.
- Hsieh 2021 [bundle:22]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=13.
- Houston 2025 [bundle:23]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=12.
- Beavers 2021 [bundle:24]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=8.
- Weaver 2021 [bundle:25]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=5. Jorgensen 2026 [bundle:9] provides animal/preclinical context only.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs negative: Lyngbaek 2024 [bundle:12] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (negative on body mass index) vs Lyngbaek 2024 [bundle:12] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Mutailipu 2026 [bundle:13] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (negative on body mass index) vs Mutailipu 2026 [bundle:13] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Tang 2021 [bundle:15]; Razny 2021 [bundle:7] (negative on body mass index) vs Tang 2021 [bundle:15] (null on body mass index) — partial conflict
- Severity 4 null vs negative: Razny 2021 [bundle:7] vs Alharbi 2023 [bundle:11]; Razny 2021 [bundle:7] (negative on body mass index) vs Alharbi 2023 [bundle:11] (null on body mass index) — partial conflict
- Severity 4 null vs positive: Kitzman 2016 [bundle:35] vs Amamou 2016 [bundle:28]; Amamou 2016 [bundle:28] (positive on body weight) vs Kitzman 2016 [bundle:35] (null on body weight) — partial conflict
- Severity 4 null vs positive: Kitzman 2016 [bundle:35] vs Reljic 2022 [bundle:1]; Reljic 2022 [bundle:1] (positive on body weight) vs Kitzman 2016 [bundle:35] (null on body weight) — partial conflict
- Severity 4 null vs positive: Aneis 2023 [bundle:17] vs Razny 2021 [bundle:7]; Razny 2021 [bundle:7] (positive on body weight) vs Aneis 2023 [bundle:17] (null on body weight) — partial conflict
- Severity 4 null vs positive: Falkenhain 2025 [bundle:5] vs Amamou 2016 [bundle:28]; Amamou 2016 [bundle:28] (positive on body mass index) vs Falkenhain 2025 [bundle:5] (null on body mass index) — partial conflict

## Major Claim Trace

- **Manuscript claim 1.** Evans 2023 [bundle:27] is a systematic review or meta-analysis of the Action for Health in Diabetes (Look AHEAD) randomized trial, developed a deficit accumulation frailty index (FI-E) spanning the 10-year intensive lifestyle intervention window. **Supporting source:** Evans 2023 [bundle:27] https://doi.org/10.1093/gerona/glad088 **Evidence span:** Methods We developed a deficit accumulation frailty index (FI-E) to span the 10 years that the Action for Health in Diabetes (Look AHEAD) randomized controlled clinical trial deli [excerpt truncated].
- **Manuscript claim 2.** Hsieh 2021 [bundle:22] is also an observational cohort analysis pooling eight six-month randomized caloric-restriction datasets in older adults (mean 67.3, SD 5.27 years) and testing whether baseline BMI and IL-6 modify gait-speed response to CR. **Supporting source:** Hsieh 2021 [bundle:22] https://doi.org/10.1093/geroni/igab046.302 **Evidence span:** We examined whether the effect of caloric restriction (CR) on gait speed change in older adults (67.3±5.27 years) varied by BMI and interleukin 6 (IL-6).
- **Manuscript claim 3.** The outcome class is therefore populated by both register-level (Hsieh 2021 [bundle:22]) and trial-level (Evans 2023 [bundle:27]) framings, with Beavers 2022 [bundle:10] supplying the individual-participant heterogeneity lens. **Supporting source:** Beavers 2022 [bundle:10] https://doi.org/10.1371/journal.pone.0267779 **Evidence span:** At baseline, participants were 67.7 (SD = 5.4) years, 69.8% female, and 79.2% white, with a BMI of 33.9 (4.4) kg/m 2 .
- **Manuscript claim 4.** In the clinical RCT evidence base, Weaver 2026 [bundle:2] randomized older adults undergoing caloric restriction with aerobic exercise to test protein supplementation effects on hip bone mineral density, cortical thickness, and bone strength endpoints (Weaver 2026 [bundle:2]). **Supporting source:** Weaver 2026 [bundle:2] https://doi.org/10.1007/s00198-026-07845-6 **Evidence span:** This trial assessed the effects of higher protein intake on hip bone outcomes in 187 older adults with overweight/obesity participating in 6 months of active WL caloric restricti [excerpt truncated].
- **Manuscript claim 5.** Houston 2025 [bundle:23] quantified body composition change in older adults, with body weight decreasing by 6.4 ± 5.4 kg (−7.0%) and fat-free mass by 2.1 ± 1.9 kg (−4.0%), while both TEE and REE declined but not significantly (TEE: Δ = −47 ± 353; source-traced values as listed) (Houston 2025 [bundle:23]). **Supporting source:** Houston 2025 [bundle:23] https://doi.org/10.1093/geroni/igaf122.1019 **Evidence span:** This degree of CR decreased body weight by 6.4±5.4 kg (-7.0%) and fat free mass (FFM) by 2.1±1.9 kg (-4.0%).
- **Manuscript claim 6.** Romashkan 2016 [bundle:31] evaluated the two-year safety of caloric restriction (CR) in non-obese, apparently healthy adults in an observational cohort design with stratified randomization (Romashkan 2016 [bundle:31]). **Supporting source:** Romashkan 2016 [bundle:31] https://doi.org/10.18632/oncotarget.8093 **Evidence span:** Although the difference in AE between AL and CR groups was not significant, within the CR group, the incidence of nervous system ( p = 0.02), musculoskeletal ( p = 0.02) and repro [excerpt truncated].
- **Manuscript claim 7.** Kip 2021 [bundle:21] (RCT, pre-operative vascular surgery patients) observed improved insulin sensitivity after four days of protein-caloric restriction (P = 0.05). **Supporting source:** Kip 2021 [bundle:21] https://doi.org/10.3390/nu13114024 **Evidence span:** Insulin sensitivity was improved after four days of PCR ( p = 0.05).
- **Manuscript claim 8.** Within-corpus tensions are most apparent between direct mechanistic/biomarker RCTs (Johnson 2026 [bundle:14], Buchowski 2012 [bundle:33], Hwang 2020 [bundle:8], Kip 2021 [bundle:21]) and indirect observational designs (Mohr 2024 [bundle:6], Bellach 2024 [bundle:19], Ko 2024 [bundle:16], Francois 2018 [bundle:30], Hugenschmidt 2019 [bundle:32], Jacobson 2023 [bundle:3]): the direct RCTs localize CR effects to discrete physiologic axes (insulin sensitivity, oxidative stress, endothelial function, fat loss), whereas the indirect cohorts distribute those same endpoints across behavioral, microbial, cognitive, and perceptual domains where effect attribution to CR per se is more difficult to isolate. **Supporting source:** Hwang 2020 [bundle:8] https://doi.org/10.3390/nu12061649 **Evidence span:** Twenty-one healthy women with obesity (age: 33 ± 2 years, body mass index: 33.0 ± 0.6 kg/m 2 ; mean ± SEM) were randomly assigned to receive either a LC diet ~10% carbohydrate ca [excerpt truncated].
- **Manuscript claim 9.** Positive signals represented by Reljic 2022 [bundle:1], Amamou 2016 [bundle:28], Mohr 2024 [bundle:6] occur alongside null signals represented by Alharbi 2023 [bundle:11], Tang 2021 [bundle:15], Hugenschmidt 2019 [bundle:32] and negative or adverse signals represented by the retained evidence base. **Supporting source:** Alharbi 2023 [bundle:11] https://doi.org/10.3390/nu15040890 **Evidence span:** Changes in body composition, REE, and systolic and diastolic BP were similar between the two interventions ( p > 0.05).
- **Manuscript claim 10.** The strongest unresolved contrast is the null vs positive between Kitzman 2016 [bundle:35] and Amamou 2016 [bundle:28] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. **Supporting source:** Amamou 2016 [bundle:28] https://doi.org/10.1007/s12603-016-0760-8 **Evidence span:** A total of 26 overweight adults aged between 60 and 75 years (BMI 32.4 ± 3.9 kg/m 2 ) with at least 2 factors of the metabolic syndrome participated in this study and were randomi [excerpt truncated].
- **Manuscript claim 11.** Review-level material such as Kitzman 2016 [bundle:35] and Houston 2018 [bundle:36] is available, but their follow-up windows and inclusion logic do not substitute for a dedicated CR-vs-control mortality trial in this population. **Supporting source:** Kitzman 2016 [bundle:35] https://doi.org/10.1001/jama.2015.17346 **Evidence span:** Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% 11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in th [excerpt truncated].
- **Manuscript claim 12.** The bulk of human evidence is concentrated in short- to medium-duration interventions (for example, the 12-week Mutailipu 2026 [bundle:13] protocol, the 8-week Tang 2021 [bundle:15] pilot) and in secondary analyses of CALERIE-derived cohorts (Jacobson 2023 [bundle:3], Falkenhain 2025 [bundle:5]). **Supporting source:** Mutailipu 2026 [bundle:13] https://doi.org/10.3389/fnut.2026.1805225 **Evidence span:** In this 12-week, open-label, non-inferiority trial, 80 participants with obesity (body mass index [BMI]: 28-40 kg/m 2 , age: 18-45 years) were randomized in a 1:1 ratio to either [excerpt truncated].
- **Manuscript claim 13.** Evans 2023 [bundle:27] reports effect direction unclear on the deficit accumulation frailty index (FI-E) at the 10-year horizon; the long-term intensive lifestyle intervention neither rescued nor worsened the index in a uniform way across the Look AHEAD cohort. **Supporting source:** Evans 2023 [bundle:27] https://doi.org/10.1093/gerona/glad088 **Evidence span:** Methods We developed a deficit accumulation frailty index (FI-E) to span the 10 years that the Action for Health in Diabetes (Look AHEAD) randomized controlled clinical trial deli [excerpt truncated].
- **Manuscript claim 14.** Evans 2023 [bundle:27] extends the mechanistic argument to a 10-year horizon, where any inflammation- or adiposity-mediated benefit of intensive lifestyle intervention would be expected to accumulate, yet the FI-E does not move in a uniform direction. **Supporting source:** Evans 2023 [bundle:27] https://doi.org/10.1093/gerona/glad088 **Evidence span:** Methods We developed a deficit accumulation frailty index (FI-E) to span the 10 years that the Action for Health in Diabetes (Look AHEAD) randomized controlled clinical trial deli [excerpt truncated].
- **Manuscript claim 15.** Evans 2023 [bundle:27], operating at the Look AHEAD systematic-review level with a 10-year deficit accumulation frailty index, also records effect direction unclear, indicating that even long-duration, intensive lifestyle intervention does not produce a clean directional shift in the FI-E. **Supporting source:** Evans 2023 [bundle:27] https://doi.org/10.1093/gerona/glad088 **Evidence span:** Methods We developed a deficit accumulation frailty index (FI-E) to span the 10 years that the Action for Health in Diabetes (Look AHEAD) randomized controlled clinical trial deli [excerpt truncated].

## References

- **Reljic 2022.** _“HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction._ Nutrients, 2022. DOI: 10.3390/nu14101996 PMID: 35631137.
- **Amamou 2016.** _Effect of a high-protein energy-restricted diet combined with resistance training on metabolic profile in older individuals with metabolic impairments._ The Journal of Nutrition, Health & Aging, 2016. DOI: 10.1007/s12603-016-0760-8 PMID: 27999852.
- **Weaver 2026.** _Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial._ Osteoporosis International, 2026. DOI: 10.1007/s00198-026-07845-6 PMID: 41553490.
- **Jacobson 2023.** _Body shape perception in men and women without obesity during caloric restriction: a secondary analysis from the CALERIE study._ Eating and Weight Disorders, 2023. DOI: 10.1007/s40519-023-01548-1 PMID: 36805838.
- **Reljic 2021.** _Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study._ Nutrients, 2021. DOI: 10.3390/nu13051640 PMID: 34068089.
- **Falkenhain 2025.** _Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2._ Scientific Reports, 2025. DOI: 10.1038/s41598-024-83762-0 PMID: 40830369.
- **Mohr 2024.** _Gut microbiome remodeling and metabolomic profile improves in response to protein pacing with intermittent fasting versus continuous caloric restriction._ Nature Communications, 2024. DOI: 10.1038/s41467-024-48355-5 PMID: 38806467.
- **Razny 2021.** _The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial._ Nutrients, 2021. DOI: 10.3390/nu13093096 PMID: 34578973.
- **Redman 2009.** _Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss._ PLoS ONE, 2009. DOI: 10.1371/journal.pone.0004377 PMID: 19198647.
- **Hwang 2020.** _The Effect of Low-Carbohydrate Diet on Macrovascular and Microvascular Endothelial Function Is Not Affected by the Provision of Caloric Restriction in Women with Obesity: A Randomized Study._ Nutrients, 2020. DOI: 10.3390/nu12061649 PMID: 32498328.
- **Jorgensen 2026.** _A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus._ Journal of Veterinary Internal Medicine, 2026. DOI: 10.1093/jvimsj/aalag040 PMID: 41818731.
- **Beavers 2022.** _Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity._ PLoS ONE, 2022. DOI: 10.1371/journal.pone.0267779 PMID: 35511858.
- **Alharbi 2023.** _Caloric Restriction (CR) Plus High-Nitrate Beetroot Juice Does Not Amplify CR-Induced Metabolic Adaptation and Improves Vascular and Cognitive Functions in Overweight Adults: A 14-Day Pilot Randomised Trial._ Nutrients, 2023. DOI: 10.3390/nu15040890 PMID: 36839248.
- **Lyngbaek 2024.** _Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial._ Journal of Sport and Health Science, 2024. DOI: 10.1016/j.jshs.2024.100999 PMID: 39427878.
- **Mutailipu 2026.** _Plant-based caloric restriction diets versus conventional calorie-restricted diets for weight loss and metabolic health in obese adults: a 12-week randomized, open-label, non-inferiority trial._ Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1805225 PMID: 42051342.
- **Johnson 2026.** _The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Loss: A Randomized Controlled Trial._ Nutrients, 2026. DOI: 10.3390/nu18111823 PMID: 42280466.
- **Francois 2018.** _Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults._ Nutrients, 2018. DOI: 10.3390/nu10060717 PMID: 29865281.
- **Tang 2021.** _Effects of Caloric Restriction and Rope-Skipping Exercise on Cardiometabolic Health: A Pilot Randomized Controlled Trial in Young Adults._ Nutrients, 2021. DOI: 10.3390/nu13093222 PMID: 34579097.
- **Ko 2024.** _Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health._ Nutrients, 2024. DOI: 10.3390/nu16193387 PMID: 39408354.
- **Romashkan 2016.** _Safety of two-year caloric restriction in non-obese healthy individuals._ Oncotarget, 2016. DOI: 10.18632/oncotarget.8093 PMID: 26992237.
- **Aneis 2023.** _Concurrent Aerobic and Strength Training with Caloric Restriction Reduces Insulin Resistance in Obese Premenopausal Women: A Randomized Controlled Trial._ Medicina, 2023. DOI: 10.3390/medicina59071193 PMID: 37512005.
- **Hugenschmidt 2019.** _Cognitive effects of adding caloric restriction to aerobic exercise training in older adults with obesity._ Obesity (Silver Spring, Md.), 2019. DOI: 10.1002/oby.22525 PMID: 31199592.
- **Buchowski 2012.** _Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial._ PLoS ONE, 2012. DOI: 10.1371/journal.pone.0047079 PMID: 23071718.
- **Coker 2012.** _Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals._ Nutrition Journal, 2012. DOI: 10.1186/1475-2891-11-105 PMID: 23231757.
- **Kim 2025.** _Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction._ Nutrients, 2025. DOI: 10.3390/nu18010083
- **Bellach 2024.** _The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women._ Nutrients, 2024. DOI: 10.3390/nu16162584 PMID: 39203721.
- **Hsu 2025.** _Caloric Restriction and Changes in Geroscience Blood-Based Biomarkers in Older Adults._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1020
- **Kip 2021.** _Short-Term Pre-Operative Protein Caloric Restriction in Elective Vascular Surgery Patients: A Randomized Clinical Trial._ Nutrients, 2021. DOI: 10.3390/nu13114024 PMID: 34836280.
- **Hsieh 2021.** _Effect of Baseline BMI and IL-6 on Gait Speed Response to Caloric Restriction in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.302
- **Houston 2025.** _Adaptations in Energy Expenditure Following Caloric Restriction in Older Adults._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1019
- **Kitzman 2016.** _Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction._ JAMA, 2016. DOI: 10.1001/jama.2015.17346 PMID: 26746456.
- **Beavers 2021.** _Appendicular Lean Mass Loss Does Not Impact Physical Performance Change During Caloric Restriction in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.301
- **Weaver 2021.** _Exercise Modality Affects Older Adult CT-Derived Muscle and Bone Loss During Caloric Restriction._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.300
- **Houston 2018.** _Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study._ J Gerontol A Biol Sci Med Sci, 2018. DOI: 10.1093/gerona/glx204 PMID: 29053861.
- **Justice 2022.** _Evaluation of a blood-based geroscience biomarker index in a randomized trial of caloric restriction and exercise in older adults with heart failure with preserved ejection fraction._ Geroscience, 2022. DOI: 10.1007/s11357-021-00509-9 PMID: 35013909.
- **Evans 2023.** _Long-term Impact of a 10-Year Intensive Lifestyle Intervention on a Deficit Accumulation Frailty Index: Action for Health in Diabetes Trial._ J Gerontol A Biol Sci Med Sci, 2023. DOI: 10.1093/gerona/glad088 PMID: 36946420.
- **Strasser 2015.** _Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults._ Eur J Nutr, 2015. DOI: 10.1007/s00394-014-0690-3 PMID: 24687684.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "6852bcae-6be1-48bf-8f00-225644f83a3b",
  "title": "Research Synthesis: Caloric Restriction Effects \u2014 full paper"
}